April 2015 Volume 11, Issue 4
Volume 11, Issue 4 | April 2015
April 2015
In this Issue
Q&A
Q&A: Berg works to ‘put Dallas back in North Texas’
DDNews speaks with Dr. Niven R. Narain, co-founder, president and chief technology officer of Berg, about his company's Interrogative Biology platform, AI and predictive modeling, Big Data and bringing more actual cures to patients instead of just reliefFeature
Massing in Missouri for mass spec
The American Society for Mass Spectrometry heads to St. Louis for its 2015 annual meetingSpecial Reports
Neuroscience Special Report: Turn on, tune in and knock out
How the flip of a switch is turning neuroscience on its headBusiness & Government Policy
Imagining a future with Imbruvica
AbbVie pays $21 billion for Pharmacyclics, nets promising cancer therapyValeant acquires Salix for more than $11 billion
Addition of U.S. company to Canadian company’s collection of acquisitions gives Valeant a GI boostPower of combining
Bristol-Myers Squibb signs agreement with Bavarian Nordic for PSA-targeting cancer immunotherapyAdvancing mRNA in vaccination
The Bill & Melinda Gates Foundation and CureVac collaborate on vaccine technologyOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsResearch & Development
Machinery of the mind
TSRI discoveries shed light on neurodegenerative disorders, including research on ‘molecular motor’A solid partnership
Freeslate to combine HTS tech with CIRCE’s predictive software to address solid state issuesGPS against cancer cells
Kite Pharmaceuticals is trying to change the landscape of immunotherapyDoes team of TG and Checkpoint mean checkmate in oncology?
Immuno-oncology deal between the two companies targets hematological malignanciesHorizon Discovery to support Cancer Research UK program
Horizon’s Diagnostics division will provide genetically defined, human genomic reference standards to Stratified Medicine ProgrammeEditor's Focus
Tech, tock; tech, tock…how long until we reveal all?
So much of our personal information is out there for consumption by corporate interests and others; new movements to use wearable tech to enhance life-sciences research and clinical trials mean your vitals might be added to that data collective, though it still may be for the best in the endCommentary
Djerassi, spring break and mass spectrometry
Find out a bit about why Carl Djerassi is such a big deal and also why mass spectrometry means so much to life sciences generally and drug discovery and development as wellCommentary: Precision medicine is not just about genetic testing
Leveraging science and technology to prevent and treat diseases based on our individual biological makeup is a potentially transformative approach that will enable us to deliver healthcare more effectively and efficiently than we ever thought possible, and one of the technological keys to that is LC-MSDiscovery
Putting a hurt on neuropathic pain
UC Davis researchers identify carboline compound that could lead to drugs to prevent neuropathic pain syndromesAdimab enters bispecific antibody deal with Sanofi
Sanofi will have the rights to all therapeutic antibodies and bispecifics resulting from the collaborationTogether on a QUEST
Cyclenium Pharma brings QUEST Library to multidrug-resistant infection collaboration with Fundación MEDINARe-Pharm finds new use for old drug
Antibiotic shows novel anti- inflammatory activity after five decades in service against noninflammatory conditionsDiagnostics
Pairing up for precision medicine
Merck Serono, Illumina to collaborate on universal NGS-based cancer diagnosticDual assay for developing world and beyond
Rheonix gets $1.5-million grant to complete development of point-of-care HIV/AIDS testPlaque Array method links blood plaque components to Alzheimer’s
Study on Plaxgen Alzheimer’s disease blood diagnostic published in peer-reviewed journalBiocept launches liquid biopsy option
Blood-based EGFR detection method can help identify who would benefit from certain NSCLC therapiesClinical Trials
Kicking the habit
Merger makes Catalyst public and advances clinical trial goals, while ending Targacept’s nicotine R&DMetAP2 mettle
Zafgen releases promising clinical results for obesity drug beloranibOn to Phase 3 for ADHD clinical trial
Alcobra’s MDX meets primary endpoint in Phase 2 trial in adolescents with attention deficit hyperactivity disorderA trio advancing trials
Taking a look at three recently announced technologies aimed at making clinical trials run more effectivelyPreclinical
Algae, mosquitoes and herd immunity
UCSD School of Medicine researchers discover malaria vaccine candidate, but funding sources dry upRight to the bone
N8 drug combo may promote osteogenesis and prevent Staphylococcus aureus infectionPreclinical data published on fast skeletal muscle troponin activator
Rat model suggests possible effectiveness in treating heart failure-related exercise intoleranceRexahn’s RX-5902 shows its mettle
Preclinical data show that Supinoxin’s mechanism of action decreases expression of several oncogenes
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Driving gene therapy with nonviral vectors
Learn why nonviral vectors are on the rise in gene therapy development.
Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis
Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Advancing immuno-oncology research with cellular assays
Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
